A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Recruiting now · Phase 1/Phase 2
Conditions studied: B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma
In brief
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Key facts
- Study ID
- NCT05643742
- Run by
- CRISPR Therapeutics AG
- People needed
- 120
- Starts
- 2023-03-10
- Expected to finish
- 2030-02-01
- Last updated by the study team
- 2025-11-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Kansas — Westwood, Kansas, United States (enrolling)
- Washington University — St Louis, Missouri, United States (enrolling)
- SCRI — San Antonio, Texas, United States (enrolling)
- University of Utah — Salt Lake City, Utah, United States (enrolling)
- Royal Prince Alfred — Camperdown, New South Wales, Australia (enrolling)
- Alfred Health — Melbourne, Victoria, Australia (enrolling)
- Sir Charles Gairdner Hospital — Nedlands, Western Australia, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.